medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Estimating the Case Fatality Ratio for COVID-19 using a
Time-Shifted Distribution Analysis
B. S. THOMAS1, N. A. MARKS1
1

Curtin University, School of Electrical Engineering, Computing and Mathematical Sciences,
Perth, Australia

Corresponding author: Nigel Marks, n.marks@curtin.edu.au
Keywords: COVID-19; Epidemics; Infectious disease epidemiology; Mathematical modelling;
SARS
Abstract
Estimating the case fatality ratio (CFR) for COVID-19 is an important aspect of public health.
However, calculating CFR accurately is problematic early in a novel disease outbreak, due to
uncertainties regarding the time course of disease and difficulties in diagnosis and reporting of
cases. In this work, we present a simple method for calculating the case fatality ratio using only
public case and death data over time by exploiting the correspondence between the time
distributions of cases and deaths. The time-shifted distribution (TSD) analysis generates two
parameters of interest: the delay time between reporting of cases and deaths and the case
fatality ratio. These parameters converge reliably over time once the exponential growth phase
has finished. Analysis is performed for early COVID-19 outbreaks in many countries, and we
discuss corrections to CFR values using excess-death and seroprevalence data to estimate the
infection fatality ratio (IFR). While CFR values range from 0.2-20% in different countries,
estimates for IFR are mostly around 0.5-0.8% for countries that experienced moderate
outbreaks and 1-3% for severe outbreaks. The simplicity and transparency of TSD analysis
enhance its usefulness in characterizing a new disease as well as the state of the health and
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
reporting
systems.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction
The novel coronavirus SARS-CoV-2, and its attendant disease, COVID-19, first appeared in
late 2019 in Wuhan, China. Since then, studies and estimates of the transmissibility and
virulence of COVID-19 have abounded, with widely varying results [1-6]. Virulence is often
measured using the case fatality ratio (also called case fatality rate or case fatality risk, CFR),
which is the number of deaths due to a disease as a proportion of the number of people
diagnosed with the disease. The CFR is dependent on the particular pathogen (and its
mechanism of action) and the immune response of the host, which can depend on age, sex,
genetic factors and pre-existing medical conditions. Environmental factors such as climate and
health system may also affect CFR. It is important to accurately quantify the CFR of a new
disease to inform policy, communication and public health measures.
Calculating the case fatality ratio requires data on cases and deaths over time, either for
individuals or populations. In general, the CFR is based on diagnosed cases of disease rather
than the number of actual infections (which is difficult to measure); there may be many more
infections than reported cases, depending on the expression of symptoms and the degree of
testing. The simplest estimate of CFR is to divide the cumulative number of deaths by the
cumulative number of cases at a given time, known as the crude (or na√Øve) CFR. However, the
crude CFR tends to underestimate the CFR during an outbreak because at any given time, some
of the existing known cases will prove fatal and need to be included in the death count. This
bias is known as right-censoring and obscures the CFR of a new disease early in the course of
the outbreak, particularly before the time course of the disease is characterised. Further, even
once the distribution of times from onset of disease to death is known, it can be difficult to use
this information to accurately correct the crude CFR. An alternative method is to use data for
closed cases only, once patients have recovered or died (eg [7, 8]), yet this information is also
difficult to obtain during an outbreak and may be biased towards a particular demographic or
2

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

skewed by delays in reporting of recoveries. Other biases in calculating CFR include underascertainment of mild or asymptomatic cases, time lags in testing and reporting, and the effects
of intervention approach, demographics and reporting schemes [9].
There are many published calculations of case fatality ratios for COVID-19 using various
datasets from different countries and using a range of methods. In some places, initial outbreaks
have now concluded and the final crude CFR accurately reflects the overall ratio of reported
deaths to cases. In many other places, outbreaks are continuing. Questions remain regarding
quality of data, methods of calculation and even the possibility of changes in the CFR over
time. These continuing uncertainties make it necessary to improve estimates of the CFR by
refining the methods used to calculate it. In essence, this means finding the best way to correct
the crude CFR for biases due to time lags and other factors. Most previously published studies
make use of a parametrised distribution of times from onset (or hospitalisation) to death,
determined from individual case data from early in the outbreak (largely from China) [5, 1012], which is then used in combination with statistical methods to estimate the CFR using
population-level data on cases and deaths [5, 10, 11, 13]. Various assumptions are made in
these analyses, including the form (and transferability) of the time course of cases, time lags in
reporting or testing or hospitalisation, and estimates of the proportion of cases being detected.
Early values of CFR obtained using these methods range from 1-18%, with the highest values
obtained for China: 4-18% early in the outbreak [5, 10], 12% in Wuhan and as low as 1%
outside Hubei province [11]. Values reported outside China include 1-5% for early cases in
travellers [5, 10], and 1-4% in Korea [13]. Case fatality ratios have also been shown to vary
greatly with the age of the patient [5], which limits the transferability of parameters based on
case studies. The specific data requirements and the range of approximations and assumptions
required by statistical methods can make it difficult to interpret or rely on the results of such
analyses, since biases can be obscured.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Time-shifted distribution analysis for COVID-19 data
The time-shifted distribution (TSD) analysis method began with an observation that the shape
of the evolving time distribution of COVID-19 cases in a given country often closely matches
the shape of the corresponding distribution of COVID-19 deaths ‚Äî simply shifted by a number
of days and linearly scaled in magnitude. This is illustrated in Figure 1 for COVID-19 cases and
deaths in Italy (data from [14], 3-day averaged data shown); the time-shifted relationship
between case and death distributions can be seen in both cumulative and daily tallies. We can
understand this shift from the perspective of the time delay between diagnosis and death or
recovery. However, the closeness of the match reflects a much simpler apparent relationship
than that suggested or assumed by conventional analyses, which relate deaths and cases using
statistical parametric models that incorporate a broad distribution of expected times between
diagnosis (or onset) and death, usually generated from case study data (e.g. [15]).
This observation suggests that there are two parameters of interest: the number of days
separating the case and death distributions (called the delay time or ùë°! ), and the scaling factor
between the time-shifted case data and the death data, ùúÜ. For the optimal value of ùë°! , there is a
simple linear relationship between cumulative number of deaths at time ùë°, ùê∑(ùë°), and cumulative
number of cases at time ùë° ‚àí ùë°! , ùê∂(ùë° ‚àí ùë°! ), with gradient ùúÜ:
ùê∑(ùë°) = ùúÜùê∂(ùë° ‚àí ùë°! )
To find the optimal value for ùë°! , we test integer values from zero to 25 days. For each value of
ùë°! , we plot ùê∑(ùë°) as a function of ùê∂(ùë° ‚àí ùë°! ) (for all ùë°) and perform a linear regression using
Matlab. The value of ùë°! is chosen on the basis of the lowest root-mean-squared error in the
linear regression analysis and the value of ùúÜ is the gradient of the corresponding line.

4

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1: COVID-19 cases and deaths in Italy to end of June (2020), using 3-day-averaged data: (a)
Cumulative cases (left-hand axis) and deaths (right-hand axis); (b) Daily cases (left-hand axis)
and deaths (right-hand axis).

Figure 2 contains the results of this analysis for Italy. Figure 2 (a) shows the error from linear
regression of ùê∑(ùë°) versus ùê∂(ùë° ‚àí ùë°! ) as a function of delay time, with a clear minimum at four
days. Figure 2 (b) shows ùê∑(ùë°) versus ùê∂(ùë° ‚àí ùë°! ) for different delay times: the optimal value of
four days (with linear fit shown) as well as some other representative values, displaying the
convergence of nonlinear to linear relationship with optimized ùë°! . Figure 2 (c) and (d) show the
excellent correlation of time-shifted and scaled case data and death data (cumulative and daily,
respectively), using a delay time of four days and a linear scaling factor of 0.144. What do these
parameters represent? The delay time is presumably a measure of the delay between reporting
of confirmed cases and reporting of COVID-19-related deaths. While four days seems very
short compared to current estimates of the mean delay between onset of COVID-19 symptoms
and death (or even between hospitalisation and death), which is around 12-22 days with a large
variance [2, 5, 7, 10, 16], it is possible to rationalise the shorter apparent delay on the basis of
delays in testing, diagnosis and reporting of the disease, particularly in countries where the
outbreak is severe. For example, in Italy from late February, testing was prioritized for ‚Äúpatients
with more severe clinical symptoms who were suspected of having COVID-19 and required
hospitalization‚Äù [17]; a subsequent delay in test results could account for the rather short delay
5

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2: Time-shifted distribution analysis for Italy: (a) Root-mean-squared error in linear regression
as a function of delay time, ùë°! ; (b) Cumulative deaths as a function of cumulative cases, timeshifted by various ùë°! values, including the optimal value of 4 days with linear regression
shown; (c) Overlay of cumulative deaths and time-shifted (and scaled) cases as a function of
time, using optimal ùë°! ; (d) Overlay of daily deaths and time-shifted (and scaled) cases as a
function of time using optimal ùë°! .

between reported diagnosis and death. This shows the inherent danger in analysing such
datasets using time-delay distributions from specific case data (which presumes a much longer
delay time). Moreover, the delay time may provide some useful information about relative
conditions in various countries.

6

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Using a time delay of four days in Italy, the scaling factor of 0.144 represents the ratio of deaths
to cases, or in other words, an estimate for the case fatality ratio, converging towards the crude
CFR with time. The calculated CFR of 14.4% is almost identical to the crude CFR of 14.5% at
the end of June, which is a good estimate for the ‚Äútrue‚Äù CFR at the end of the outbreak. An
interesting question is, at what point in the outbreak does the CFR calculated using the TSD
analysis give a good approximation to the final value? This is important because early estimates
of CFR are vital for informing public health decisions. Figure 3 shows the CFR calculated at
various stages of the outbreak using data available to that point. Errors represent uncertainty in
the linear regression as well as in ùë°! . The earliest data predict a longer delay time, which results
in a higher predicted CFR; once the value of ùë°! has stabilised (from 26 March), the predicted
value of CFR is also very stable, and also remarkably accurate (14.4%), compared to the crude
value of 10.3% at that time. Even a week earlier, the calculated CFR of 16.6% is a better
estimate than the crude estimate of 8.4%.
It appears that this simple analysis generates two parameters of significant interest: the apparent
delay between reporting of related cases and deaths, and the CFR. The estimates of these
parameters (which can be determined unequivocally once an outbreak is concluded) can be
calculated during the course of an outbreak and give a better approximation than the crude
CFR. It should be noted that such an analysis cannot be applied during purely exponential
growth, because time-shifting (horizontally) and scaling (vertically) an exponential function are
equivalent operations, as: ùê¥ùëí "($%$!) = [ùê¥ùëí %"$! ]ùëí "$ = ùê∂ùëí "$ , which means that any value of ùë°!
will give an equivalent relationship between ùê∂(ùë° ‚àí ùë°! ) and ùê∑(ùë°) with gradient depending on ùë°! .
Therefore, the TSD analysis is only valid once exponential growth ends and the daily case rate
is approaching (or past) its peak. Alternatively, an estimate for ùë°! could be used, but this
reduces the simplicity and transparency of the model. We note that others have calculated an
‚Äúadjusted‚Äù CFR early in the COVID-19 outbreak using an equivalent method with an assumed
7

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 3: Calculated case fatality ratio (using TSD analysis) for COVID-19 in Italy (2020) as a function
of time during an outbreak, alongside the crude CFR.

value of the time delay between onset and death (because the true value was not known): Yuan
and colleagues [18] chose sample values of one, three and five days to give estimates from 313% for Italy in early March, while Wilson and colleagues [19] used 13 days to give 0.8-3.5%
for China in early March.
Application of TSD analysis to SARS 2003 outbreak in Hong Kong
To test the TSD analysis method in determining CFR in the middle of an outbreak, and
compare to alternative methods, we analyse data from the SARS 2003 outbreak in Hong Kong
(17 March to 11 July), obtained from the World Health Organization [20] and 3-day averaged.
Figure 4 shows the cumulative and daily number of SARS cases and deaths in Hong Kong as a
function of time.

8

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 4: SARS cases and deaths in Hong Kong (2003), using 3-day averaged data: (a) Cumulative
cases (left-hand axis) and deaths (right-hand axis); (b) Daily cases (left-hand axis) and deaths
(right-hand axis).

It is apparent in Figure 4 that, as for COVID-19 data in Italy, the shapes of the distributions of
cases and deaths are analogous. Time-shifted distribution analysis gives the following at the
end of the outbreak: delay time is 22 days, and calculated CFR is 16.7%, close to the final crude
CFR of 17.0%. The linear fit is reasonable given the noise in the data, as shown in Figure 5. If
we perform TSD analysis serially over the course of the outbreak, reasonable estimates can be
obtained from 17 April, giving values of 12-17% (with delay times of 17-22 days) converging
on 16.7%, as shown in Figure 6. To compare, on 17 April the crude CFR is 5.3%, which is a
significant underestimate of the true value. The delay time of 22 days is consistent with
observations that the delay between onset and death for SARS is approximately three weeks
[21]. We also applied TSD analysis to SARS data for other countries, giving a calculated CFR
of 15% for Singapore and Canada (although data are noisy), and 13% for Taiwan.
We can compare these estimates of the CFR with the more complex mathematical models of
Nishiura and coworkers [22] and Ghani and coworkers [15] for the same SARS outbreak. The
simple TSD analysis gives better predictions than both the parametric mixture model and
modified Kaplan-Meier method described by Ghani et al. [15], which use individual case data

9

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 5: Time-shifted distribution analysis of SARS (2003) data for Hong Kong: (a) Root-meansquared error in linear regression as a function of delay time, ùë°! ; (b) Linear regression for
cumulative number of deaths as a function of cumulative number of cases (time-shifted by
optimal ùë°! ); (c) Overlay of cumulative deaths and time-shifted (and scaled) cases as a function
of time, using optimal ùë°! ; (d) Overlay of daily deaths and time-shifted (and scaled) cases as a
function of time, using optimal ùë°! .

(dates of hospitalisation and death or discharge from hospital) to estimate CFR using statistical
methods. Such methods can provide earlier estimates (from 1 April, giving around 7-8% CFR)
but are less accurate at this early stage than a simple estimate of CFR from data on closed cases
(recoveries and deaths) at the same dates [15], and are later outperformed by our simple TSD

10

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 6: Calculated case fatality ratio (using TSD analysis) for SARS in Hong Kong (2003) as a
function of time during an outbreak, alongside the crude CFR.

method once sufficient data to perform the analysis are available. Further, TSD analysis
requires only publicly reported case and death data (over time), which is easier to obtain than
individual case data including onset dates.
Similarly, the model of Nishiura et al. [22] can provide much earlier estimates of CFR than our
analysis but the accuracy of these estimates is uncertain and depends on the assumptions made.
Their analysis requires data on the dates of onset of confirmed cases and the distribution of
times from onset to death; the latter, in particular, is poorly known at the start of an outbreak of
a new disease. Nishiura et al. [22] analyse the Hong Kong SARS data by assuming a simple
exponential distribution for the time between onset and death, with a mean of 36 days (from
Donnelly [21] for SARS cases in Hong Kong up to 28 April, although Donnelly used a gamma

11

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

distribution), and using statistical sampling to predict the CFR. The fact that this model
provides a reasonable prediction of CFR at a specific time (around the end of March) is likely
fortuitous, given that it involves scaling the crude CFR by a constant factor and will therefore
overestimate the CFR at later times (as well as very early times). Further, this method requires
the use of parametrised data (the time distribution for onset to death) that are not available at
the time that the predictions are purported to be made. In fact, when Nishiura et al. [22] apply
the method to early H1N1 (swine flu) data in 2009 they are forced to use a time distribution
calculated from historical data for H1N1 (Spanish) influenza from 1918-1919, which is
problematic; a sensitivity analysis shows that the predicted CFR is sensitive to the choice of
distribution parameters, making this method somewhat difficult to apply in the circumstances
for which it is proposed.
In comparison, the time-shifted distribution analysis is both transparent and straightforward to
implement, using only publicly available data and no assumptions, and can provide a
reasonably early estimate (once exponential growth has sufficiently slowed) of CFR that
converges to the ‚Äútrue‚Äù value. If the value of the time delay is approximately known early in the
outbreak, this could be used to constrain the fitting procedure, but as observed already, it is
difficult either to know the time delay between onset and death or to apply it to the time delay
between reporting of cases and deaths.
Time-shifted distribution analysis of international COVID-19 data
Time-shifted distribution analysis was performed on COVID-19 data from an extensive range
of countries, using datasets from Johns Hopkins Center for Systems Science and Engineering
[14], cross-checked and supplemented with data from Worldometers.com and 3-day averaged.
For most countries (as for Italy), the analysis results in a robust linear fit and provides a stable
estimate for CFR and delay time. These data are shown in Table 1, organised by region

12

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(Europe, Middle East, Asia, Oceania, North/Central America, South America, Africa) and then
by CFR (decreasing). The corresponding plots of cases and deaths for each country are included
in Appendix 1, to demonstrate the astonishing correlation between case and death time profiles
over a huge range of locations and outbreak characteristics. For some few countries, either the
data are insufficiently resolved (for example, still in exponential growth or very low numbers)
or too noisy or unreliable for rigorous analysis. For other countries, the linear correlation is not
robust and varies over time; notable examples are Sweden, Brazil and the USA, which are
discussed in the following section. For countries listed in Table 1, most analyses use data up
until the end of May, which is generally representative of the initial outbreak; for some
countries with later outbreaks, later end dates are used. In many countries, more recent
outbreaks have had dramatically different CFR values to initial outbreaks (due largely to
improved testing rates); these can be analysed independently by selecting the time frame
studied, but values presented here are for the initial outbreak in each country.
The most notable result is the huge range in both delay times and calculated CFR estimates
over different countries: from zero to 24 days‚Äô delay and from less than one to 20% case fatality
ratio. The highest ratios are calculated in Western Europe (up to 20%), followed by North
America (up to 15%), South America (up to 10%), Africa (up to 7%), and lowest in the Middle
East, Asia and Oceania (up to 5%). It is problematic to draw conclusions about relative
COVID-19 virulence by comparing CFR values between countries, because of vast differences
in testing and reporting regimes ‚Äî in particular, the under-reporting of cases (including mild or
asymptomatic cases) due to inadequate testing, but also differences in classification or
recognition of COVID-19-related deaths. However, it is instructive to calculate in this way, for
any given country, the proportion of detected cases that are currently proving fatal, for the
purposes of public health management and planning. For comparison, Mazumder and
colleagues [8] calculated case fatality ratios for a range of countries using recovery and death

13

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1: Case fatality ratio values and delay times calculated using time-shifted distribution analysis for
a range of countries (initial outbreak), ordered by region and by CFR.
Country

CFR (%)

Delay Time (days)

End Date

Europe
France

20

7

May 31

Belgium

17

6

May 31

UK

16

3

May 31

Italy

14

4

May 31

Hungary

14

8

May 31

Netherlands

13

4

May 31

Sweden

13

5

May 31

Spain

11

14

May 31

Romania

7

6

May 31

Ireland

7

7

May 31

Slovenia

7

15

May 31

Bulgaria

6

7

May 31

North Macedonia

6

8

May 31

Greece

6

8

May 31

Poland

6

8

May 16

Switzerland

6

11

May 31

Denmark

5

4

May 31

Finland

5

9

June 30

Germany

5

13

May 31

Croatia

5

18

May 31

Portugal

4

7

May 31

Czechia

4

11

May 31

Austria

4

13

May 31

Estonia

4

13

May 31

Moldova

3

0

July 31

Ukraine

3

4

May 31

Norway

3

13

May 31

Luxembourg

2.6

10

May 31

Latvia

2.6

23

May 31

14

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1 continued‚Ä¶
Serbia

2.1

1

May 31

Armenia

2.0

7

July 31

Russia

1.8

14

July 31

Azerbaijan

1.5

6

July 31

Middle East
Iraq

5

5

July 16

Egypt

5

8

July 31

Afghanistan

3

10-17

July 31

Turkey

2.8

3

May 31

Israel

1.6

10

May 31

Saudi Arabia

1.2

14

July 31

Kuwait

0.8

2

June 30

Oman

0.6

6

July 31

Qatar

0.17

21

July 31

Asia
Japan

5

14

June 30

China

4

6

March 31

India

3

0

May 31

South Korea

2.4

18

June 30

Pakistan

2.1

2

July 31

Thailand

1.9

9

May 31

Malaysia

1.7

2

May 31

Taiwan

1.5

4-5

May 31

Bangladesh

1.3

1

July 31

Oceania
New Zealand

1.5

17

June 30

Australia

1.4

12

May 31

North/Central America
Mexico

11

0

August 31

Canada

9

10

June 30

USA

7

4

May 31

Guatemala

4

0

August 31

15

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1 continued‚Ä¶
Cuba

4

4

May 31

Panama

3

2

May 31

South America
Ecuador

10

12

May 31

Bolivia

5

7

August 31

Brazil

3

0

August 31

Colombia

3

0

August 31

Peru

3

5

June 30

Chile

3

18

August 31

Argentina

2.4

7

August 31

Venezuela

0.8

0

August 31

French Guiana

0.7

12

September 30

Africa
Sudan

7

4

July 31

Tunisia

4

3

May 31

Senegal

2.3

14

September 30

Nigeria

2.3

0

July 31

South Africa

2.4

14

September 30

Ethiopia

1.6

0

September 30

Mayotte

1.3

1-2

May 31

Gabon

0.7

0

August 31

Guinea

0.6

3

August 31

data from closed cases. They analysed eleven countries with high outcome rates and sufficient
progression in the outbreak for analysis (at the end of April), but many of their calculated CFR
values are much higher than our estimates ‚Äî for example, estimated CFR above 30% for Italy,
France and USA at the end of April ‚Äî probably due to delays in recovery reporting, whereas
estimated CFR values for Germany, China and South Korea match ours. The TSD analysis
provides more reliable estimates for a broader range of countries, due to the greater availability
of death and case data over recovery data.

16

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

The differences in delay times are also startling, ranging from zero to 24 days with no clear
pattern. This delay between reported cases and deaths may be informative regarding the state of
reporting or testing in a country but it is difficult to interpret. The mean delay between onset of
symptoms and death has been estimated at 12-22 days using case data [2, 5, 7, 10, 12, 16], but
there are also delays between onset of symptoms and testing, between testing and reporting of
results, and in reporting of deaths. For example, in Sweden a mean delay of five days between
onset of symptoms and the ‚Äústatistical date‚Äù of a reported case (including one day from test to
statistic) was reported [7]. In some countries, tests are only administered to the sickest patients
(many days after onset), and in others, test results can take up to a few weeks. We note that for
Australia and New Zealand, where case numbers have been low and testing extensive and rapid,
the calculated time delay is more than ten days, whereas many of the harder-hit countries in
western Europe and North America have much shorter calculated time delays.
Spain is an interesting case. Until 12 August, TSD analysis using Spanish data from the
Worldometer website [23] gave a stable CFR of 10% with a delay time of one day. On that day,
data were ‚Äúadjusted retrospectively by national authorities: case counts adjusted from 2
February to 11 August and death counts adjusted from 26 April to 11 August‚Äù according to the
World Health Organisation (WHO) [24]. Using the revised data, the TSD analysis provided an
even more robust fit; the CFR was almost unchanged at 11% but the delay time was increased
to 14 days. This means that early data from Spain, which were erratic, reflected a much shorter
delay between reported cases and deaths. In fact, the death data were largely unaffected by the
August revision, but the dates of reported cases had shifted nearly two weeks earlier,
presumably to better capture the onset time. This shows that a short delay time can reflect late
reporting of cases, due either to testing late in the progress of the disease (well after onset) or
delays in providing test results (or both). This may explain the short delay times for the United
Kingdom, Italy, the Netherlands and the USA, as well as many other countries (for example,

17

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

zero days‚Äô delay in Mexico). For countries that demonstrated reliable contact-tracing and
testing regimes, such as Australia, New Zealand and Germany, delay times are close to 14 days,
similar to the revised Spain data and consistent with the estimated time course of fatal disease.
An important conclusion from this analysis concerns the perils in calculating the CFR using
established time distributions for onset to death obtained from case studies, as is common. The
beauty of this simple method is its transparency ‚Äî nothing is assumed and the data are enabled
to speak for themselves, and can therefore give us information that we might not expect, rather
than merely reflecting our assumptions.
Discussion
We are interested not only in the versatility and simplicity of this method, but also in what
conclusions may be drawn from the parameters calculated ‚Äî namely, the CFR and the delay
time. Reported CFR values for COVID-19 vary widely, but the best current estimates of the
true infection fatality ratio or IFR (taking into account all infections including undiagnosed and
asymptomatic) are around 0.6-0.7% [4, 6] based on cruise ship and population serology data.
The very high CFR values calculated for many European countries in particular are probably
vastly inflated due to the inadequate testing and overwhelmed health systems in these countries,
which result in underestimation of case numbers. However, it is an oversimplification to
assume that this is the only relevant factor that differs between countries, since we know that
demographics and health systems (among other things) can also affect survival probability.
Such an assumption has been used in various studies, in order to compare the effectiveness of
different countries' reporting systems and to correct case numbers [4, 25]. However, by
assuming that the IFR is identical everywhere at all times, valuable information is lost and
conclusions may be misleading.

18

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

In this study, we estimate the IFR from the CFR for a subset of countries using seroprevalence
data (to correct case numbers) and excess death data (to correct death numbers). Along similar
lines, Ioannidis [26] previously estimated the IFR for various countries using seroprevalence
data and cumulative reported deaths at a corresponding date, although this does not account for
either excess deaths or the relationship between cases and deaths over time; in fact, using
seroprevalence and death data alone reintroduces the issue of the unknown time delay between
cases and deaths, which must be approximated. We note that studies from very early in the
pandemic provided initial estimates for the true prevalence of COVID-19 in specific places; a
spatiotemporal transmission model applied to Wuhan [27] gave a prevalence factor of seven in
January (published mid-March), and a statistical analysis study of testing data in the USA [28]
estimated a prevalence factor of nine in April (published in May). These early prevalence
studies can be useful in roughly correcting the CFR to estimate the IFR before rigorous
seroprevalence data are available.
In Australia, case numbers have been generally low (especially before June) and testing rates
high. It is unlikely that there have been appreciable unreported COVID-related deaths [29].
However, even with robust testing many cases will be undiagnosed, especially asymptomatic
cases, which could constitute half of all infections [30]. A recent seroprevalence study of
elective surgery patients in four states [31] estimated that the number of true infections was
around 5-10 times the number of reported cases, although the authors state that the study cohort
may not reflect the general population (older individuals overrepresented). This prevalence ratio
gives an approximate IFR for Australia of 0.1-0.3%. Note that before June, most of Australia's
COVID-19 cases were returned travellers, which may affect the age distribution and baseline
health of cases compared to the general population. New Zealand, Taiwan and Thailand are
similarly circumstanced and have very similar CFR values, which are expected to reflect similar
IFR values to Australia. Singapore, with its extremely low fatalities and extensive testing, did

19

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

not return a robust result from TSD analysis; nonetheless, the crude CFR of 0.07% at the end of
May is likely a lower bound for the IFR.
The USA is an interesting case study. The TSD analysis is problematic because the relationship
between cases and deaths changes over time, causing mismatch between case and death
distributions and a downward drift in both CFR and delay time. This may be due to incomplete
data, or changes in testing or reporting over time, which can affect both delay time and case
numbers. Alternatively, the case fatality ratio may be truly changing over time, due to changes
in treatment approach or in the demographics (or location) of COVID-19 cases [32]. In the
USA, there is also heterogeneity between states. To demonstrate, we present the time-shifted
distribution analysis for the USA in Figure 7, and for the state of New Jersey (which has the
highest mortality rate in the USA) in Figure 8. For the USA as a whole, there is clear variation
over time in the relationship between time-shifted case and death data, demonstrated in both the
poor linear fit and the mismatch in distribution profiles. If we scrutinise individual state data,
some US states (including New Jersey, Illinois, Massachusetts, New Mexico, Ohio and
Pennsylvania) manifest a very reliable TSD analysis, but others do not (for example, California,
North Carolina, Oklahoma and Texas). Data from New Jersey (Figure 8) give a stable CFR
around 8-9%, comparable to New York, Massachusetts and Pennsylvania, while Ohio gives 7%
and Illinois and New Mexico give 5%.
One potential reason for the mismatch of case and death data in the USA as a whole (and many
of its states) is the under-reporting of cases due to the low level of testing, which varies over
time. One measure of the adequacy of testing is the share of daily COVID-19 tests that return a
positive result, known as the positive test rate (PTR). The WHO has suggested a PTR around
3-12% (or less) as a benchmark of adequate testing [33]. In the USA, the positive test rate
reached maximum levels in April, with values between 18 and 22% from 1-21 April [33],

20

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 7: Time-shifted distribution analysis for USA at the end of August: (a) Root-mean-squared error
in linear regression as a function of delay time, ùë°! ; (b) Linear regression for cumulative
number of deaths as a function of cumulative number of cases (time-shifted by optimal ùë°! ); (c)
Overlay of cumulative deaths and time-shifted (and scaled) cases as a function of time, using
optimal ùë°! ; (d) Overlay of daily deaths and time-shifted (and scaled) cases as a function of
time, using optimal ùë°! . Note the mismatch between distributions of death and cases.

which is the region of greatest discrepancy between case and death profiles in the initial
outbreak, as seen in Figure 7. We would expect that such a high PTR indicates that case
numbers during this time are greatly underestimated, which may explain the poor fit from TSD
analysis and the high CFR. Similar effects are seen in data from Sweden and Brazil, which also
had low and variable testing rates and high PTR. Recent seroprevalence studies in many states
21

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 8: Time-shifted distribution analysis for New Jersey: (a) Root-mean-squared error in linear
regression as a function of delay time, ùë°! ; (b) Linear regression for cumulative number of
deaths as a function of cumulative number of cases (time-shifted by optimal ùë°! ); (c) Overlay of
cumulative deaths and time-shifted (and scaled) cases as a function of time, using optimal ùë°! ;
(d) Overlay of daily deaths and time-shifted (and scaled) cases as a function of time, using
optimal ùë°! .

of the USA from March to May [34] suggest that there were at least eleven times as many
infections as reported cases before the end of May. Excess death data indicate that COVIDrelated deaths may be higher than reported by a factor of 1.4 for the same period [35]. Using
these correction factors for the CFR, the estimated IFR for the USA is 1.0% or below. For

22

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

comparison, a Worldometers calculation estimated an IFR of 1.4% in New York City in May
[23], using a prevalence ratio of ten from an early antibody study [36, 37].
In Europe, many of the most affected countries have very high case fatality ratios, often
combined with relatively short delay times. For some of these countries, seroprevalence studies
provide estimates of the degree of undercounting of cases during the initial outbreak [38-46],
which can be utilised along with excess death data [35] to estimate the infection fatality ratio.
These IFR values are shown in Table 2 along with the correction factors used. Some of the
seroprevalence data is preliminary, including studies of Germany, Sweden and Italy, and others
are for specific regions of the country and may not be representative. Nonetheless, the estimated
IFR values are reasonable: Switzerland and Germany are around 0.6%, above Australia and
below Sweden and USA at around 0.8%; Belgium, UK and Spain are between one and two
percent; and Italy higher at around 3%. Ioannidis [26] also calculated the IFR for many of these
countries using seroprevalence studies, but using only single-time seroprevalence and death
data with an assumed delay time (generally a week after the midpoint of the seroprevalence
survey); these are also shown in Table 2 and are broadly consistent with our values except
where excess deaths are significant (e.g. Spain). Our value for Germany is somewhat higher but
we expect that it is more reliable, using the scaling factor for cases [38] with our calculated
CFR rather than the absolute number of deaths at a certain date in the German town of Gangelt
[26], which is very low and reflects a date early in the German outbreak.
Although the calculated IFR values are only approximate and subject to revision, it is
conceivable that higher IFR values may reflect higher fatality ratios in particular places at
particular times, due to overwhelmed health systems in hard-hit areas or specific demographics
or baseline health of affected populations. For example, it is reasonable to conclude that in
Lombardy, Italy, the older population and overwhelmed health system caused a higher fatality

23

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2: Estimated IFR from CFR (calculated in this work), using scaling factors from seroprevalence
and excess death data.
Country

2

Scaling factors

IFR estimate
[this work]

IFR from
Ioannidis1 [26]

Deaths
(excess)

Cases
(prevalence)

1.4

1.0

5-10 [31]

0.1-0.3

Switzerland

6

1.0

10-12 [39]

0.5-0.6

0.45

Germany

5

0.8

5-7 [38]

0.5-0.8

0.28

Sweden

13

1.2

17-21 [40]

0.7-0.9

0.71

USA2

7

1.4

9-13 [34]

0.7-1.0

0.65

Belgium

17

1.0

13-15 [42]

1.1-1.3

1.09

UK

15

1.3

14-15 [41]

1.3-1.4

Spain

11

1.5

9-12 [43, 44]

1.3-1.8

Italy

14

1.5

6-7 [45, 46]

3.0-3.5

Australia

1

CFR
[this work]

1.15

IFR from Ioannidis [26] uses seroprevalence and concomitant deaths at a single time point.
USA value is a weighted mean of six states.

ratio compared to other places. In fact, the difference in age distribution of cases between Italy
and Australia up to the end of May (using data from [47] and [48]) can alone account for a
factor of three in the IFR. Therefore, while differences in testing and reporting between
different countries undoubtedly account for much of the variation in IFR between countries, we
neither expect nor find that IFR is the same for all COVID-19 outbreaks. Country-specific
factors that influence IFR and differ between countries include testing and reporting, age
demographics [49], health-care systems and treatments [32], mask-wearing and other
behaviours, climate and culture, transport infrastructure and community mobility [50], genetic
factors or prevalence of particular antibodies that affect immune response [51].
There is some evidence that the IFR might be decreasing over time in some countries,
especially those experiencing a ‚Äúsecond wave‚Äù. This is observed, for example, in the data for
the USA in Figure 7, demonstrated in the increasing mismatch in case and death distributions

24

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

later in the outbreak. We can use the TSD analysis to analyse the latter part of the outbreak
(from July to September), giving a CFR of 1.5-1.7% and a delay time of 2-3 weeks. Similar
analyses for individual states of the USA give stable CFR values from 1.1-2.3% with delay
times between four and 24 days, with a mean of 1.6% CFR and 17 days‚Äô delay over states with
robust fits. This later CFR is far lower than the value of 7% calculated early in the outbreak.
We observe similar effects in various other countries post-July including Japan (reduced to
1.1% and 22 days‚Äô delay) and Spain, France and Portugal (all reduced to 0.8-1.3%, 12-29 days‚Äô
delay). These values are all similar and may reflect a reasonable estimate for CFR when testing
is adequate; we would still expect the IFR to be lower by a factor of at least two due to
undiagnosed and asymptomatic cases. A decrease in CFR over time may also indicate a change
in the demographics of the case load or improvements in treatment or even an increasing time
delay between reported cases and deaths, perhaps due to earlier diagnosis.
We also find that, in countries where the time delay is significant, the TSD analysis can serve in
a predictive capacity for numbers of deaths, using the linear relationship between deaths and
time-shifted cases. Figure 9 shows this prediction for the second phase of the COVID-19
outbreak in France from August. Using parameters calculated from TSD analysis for August to
mid-October, reported case data can be time-shifted and linearly scaled to predict daily deaths
for France for the next three weeks. This is useful for public health planning, as well as
decision-making regarding implementation of restrictions.
Conclusion
The time-shifted distribution analysis is a straightforward way to predict CFR over time, using
only publicly available data on cases and deaths and requiring no assumptions or
parametrisations regarding the progress of the illness. The beauty of this method is in its
transparency and simplicity; the lack of assumptions allows more to be gained from the data,

25

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 9: Using TSD analysis to predict deaths over time based on case data, delay time and CFR in
France from August. Prediction uses 3-day averaged case data up to 16 October, shifted (20
days) and linearly scaled using the CFR (0.8%).

including trends that may be unexpected or changing over time. This analysis method has
particular utility early in an outbreak, once sufficient data are available for a robust fit (beyond
the exponential growth phase). Without the benefit of hindsight, the TSD-calculated values for
CFR and time delay between cases and deaths can shed light on the virulence of a disease and
on the conditions that a particular country may be facing. Excess death data (where available)
may be used to correct death data, while positive test rates and other indicators or models of
testing adequacy can often give an early rough idea of the true prevalence relative to reported
case numbers. These data can be used to interpret the CFR calculated using TSD analysis early
in an outbreak, and to approximate the IFR.

26

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Our estimates of IFR range from 0.3-3%, with higher values observed for countries that
experienced more severe outbreaks, perhaps reflecting the negative influence of overwhelmed
health systems and the spread of disease to more vulnerable populations. The calculated time
delay is also potentially informative; for example, the one-day delay calculated from early data
in Spain reflects the breakdown of testing and reporting systems at that time, whereas the
revised delay time of 14 days shows the recovery of the system and the likely delay between
case diagnosis and death. In this way, TSD analysis of data from a particular place at a
particular time can give useful local information on the progression of an outbreak to inform
public health planning and policy.
Acknowledgements
We thank Dr Nick Golding (Curtin University) for many helpful conversations and comments
on the manuscript.
Data Availability Statement
The data used this study are publicly available. COVID-19 data are from the COVID-19 Data
Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins
University at https://github.com/CSSEGISandData/COVID-19 (via
https://github.com/pomber/covid19), and from Worldometer at
https://www.worldometers.info/coronavirus/. SARS data are from the World Health
Organization at https://www.who.int/csr/sars/country/en/ (via
https://www.kaggle.com/imdevskp/sars-outbreak-2003-complete-dataset). Excess death data
are from the Economist‚Äôs COVID-19 excess deaths tracker repository at
https://github.com/TheEconomist/covid-19-excess-deaths-tracker, and positive COVID-19 test
rates are from Our World in Data at https://ourworldindata.org/coronavirus-testing.

27

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

References
(1)

Li Q, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-

Infected Pneumonia. New England Journal of Medicine 2020; 382(13): 1199-1207.
doi:10.1056/NEJMoa2001316.
(2)

Linton NM, et al. Incubation Period and Other Epidemiological Characteristics of 2019

Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly
Available Case Data. Journal of Clinical Medicine 2020; 9(2): 538. doi:10.3390/jcm9020538.
(3)

Rajgor DD, et al. The many estimates of the COVID-19 case fatality rate. The Lancet

Infectious Diseases 2020; 20(7): 776-777.
(4)

Russell TW, et al. Estimating the infection and case fatality ratio for coronavirus

disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise
ship, February 2020. Eurosurveillance 2020; 25(12): 2000256.
(5)

Verity R, et al. Estimates of the severity of coronavirus disease 2019: a model-based

analysis. The Lancet Infectious Diseases 2020; 20(6): 669-677. doi:10.1016/s14733099(20)30243-7.
(6)

Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published

research data on COVID-19 infection-fatality rates. International Journal of Infectious
Diseases 2020: in press. doi:10.1016/j.ijid.2020.09.1464.
(7)

Public Health Agency of Sweden. The infection fatality rate of COVID-19 in

Stockholm ‚Äì Technical report: Public Health Agency of Sweden; 202020094-2.
www.folkhalsomyndigheten.se/publicerat-material/.
(8)

Mazumder A, et al. Geographical variation in case fatality rate and doubling time

during the COVID-19 pandemic. Epidemiology & Infection 2020; 148: 1-12.

28

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(9)

Angelopoulos AN, et al. On Identifying and Mitigating Bias in the Estimation of the

COVID-19 Case Fatality Rate. Harvard Data Science Review 2020.
doi:10.1162/99608f92.f01ee285.
(10)

Dorigatti I, et al. Report 4: severity of 2019-novel coronavirus (nCoV). Imperial

College London, London 2020.
(11)

Mizumoto K, Chowell G. Estimating Risk for Death from Coronavirus Disease, China,

January-February 2020. Emerging Infectious Diseases 2020; 26(6): 1251-1256.
(12)

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel

coronavirus (2019-nCoV) in Wuhan, China. Journal of Medical Virology 2020; 92(4): 441-447.
doi:10.1002/jmv.25689.
(13)

Shim E, et al. Estimating the Risk of COVID-19 Death During the Course of the

Outbreak in Korea, February‚ÄìMay 2020. Journal of Clinical Medicine 2020; 9(6): 1641.
(14)

Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in

real time. The Lancet Infectious Diseases 2020; 20(5): 533-534.
(15)

Ghani AC, et al. Methods for estimating the case fatality ratio for a novel, emerging

infectious disease. American Journal of Epidemiology 2005; 162(5): 479-486.
doi:10.1093/aje/kwi230.
(16)

Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2

pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet
Respiratory Medicine 2020; 8(5): 475-481. doi:10.1016/s2213-2600(20)30079-5.
(17)

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients

dying in relation to COVID-19 in Italy. JAMA 2020; 323(18): 1775-1776.
(18)

Yuan J, et al. Monitoring transmissibility and mortality of COVID-19 in Europe.

International Journal of Infectious Diseases 2020; 95: 311-315.

29

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(19)

Wilson N, et al. Case-fatality risk estimates for COVID-19 calculated by using a lag

time for fatality. Emerging Infectious Diseases 2020; 26(6): 1339-1441.
(20)

World Health Organization. Cumulative Number of Reported Probable Cases of

Severe Acute Respiratory Syndrome (SARS). https://www.who.int/csr/sars/country/en/.
Accessed at https://www.kaggle.com/imdevskp/sars-outbreak-2003-complete-dataset, June 30,
2020.
(21)

Donnelly CA, et al. Epidemiological determinants of spread of causal agent of severe

acute respiratory syndrome in Hong Kong. The Lancet 2003; 361(9371): 1761-1766.
(22)

Nishiura H, et al. Early epidemiological assessment of the virulence of emerging

infectious diseases: a case study of an influenza pandemic. PLoS One 2009; 4(8): e6852.
(23)

Worldometer. Coronavirus (COVID-19) Mortality Rate.

https://www.worldometers.info/coronavirus/coronavirus-death-rate/, May 14, 2020.
(24)

World Health Organization. Coronavirus disease (COVID-19): Log of major changes

and errata in WHO daily aggregate case and death count data. August 23, 2020. Retrieved from
https://www.who.int/publications/m/item/log-of-major-changes-and-errata-in-who-dailyaggregate-case-and-death-count-data.
(25)

Kuster AC, Overgaard HJ. A novel comprehensive metric to assess COVID-19

testing outcomes: Effects of geography, government, and policy response. Medrxiv 2020.
doi:10.1101/2020.06.17.20133389.
(26)

Ioannidis J. Infection fatality rate of COVID-19 inferred from seroprevalence data.

Bulletin of the World Health Organization 2020: Article ID BLT.20.265892, in press,
https://www.who.int/bulletin/online_first/BLT.265820.265892.pdf.
(27)

Li R, et al. Substantial undocumented infection facilitates the rapid dissemination of

novel coronavirus (SARS-CoV-2). Science 2020; 368(6490): 489-493.

30

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(28)

Wu SL, et al. Substantial underestimation of SARS-CoV-2 infection in the United

States. Nature Communications 2020; 11(1): 1-10.
(29)

Martino M. How accurate are Australia's coronavirus numbers? The answer lies in our

death data. https://www.abc.net.au/news/2020-06-23/coronavirus-australia-excess-deaths-dataanalysis/12321162, June 23, 2020.
(30)

Lavezzo E, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of

Vo‚Äô. Nature 2020; 584(7821): 425-429.
(31)

Hicks S, et al. A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody

seroprevalence in a low transmission setting. Journal of Infectious Diseases 2020: jiaa623, in
press. doi:10.1093/infdis/jiaa623.
(32)

von K√ºgelgen J, Gresele L, Sch√∂lkopf B. Simpson's paradox in Covid-19 case fatality

rates: a mediation analysis of age-related causal effects. arXiv preprint 2020:
arXiv:2005.07180.
(33)

Our World in Data. Coronavirus (COVID-19) Testing.

https://ourworldindata.org/coronavirus-testing. Accessed 16 July, 2020.
(34)

Havers FP, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the

United States, March 23-May 12, 2020. JAMA Internal Medicine July 21, 2020.
doi:10.1001/jamainternmed.2020.4130.
(35)

The Economist. Tracking covid-19 excess deaths across countries.

https://www.economist.com/graphic-detail/2020/07/15/tracking-covid-19-excess-deaths-acrosscountries. Accessed 15 October, 2020.
(36)

Rosenberg ES, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in

New York. Annals of Epidemiology 2020; 48: 23-29.
(37)

New York State Government. Amid Ongoing COVID-19 Pandemic, Governor Cuomo

Announces Results of Completed Antibody Testing Study of 15,000 People Showing 12.3

31

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Percent of Population Has COVID-19 Antibodies; May 2, 2020.
https://www.governor.ny.gov/news/amid-ongoing-covid-19-pandemic-governor-cuomoannounces-results-completed-antibody-testing.
(38)

Streeck H, et al. Infection fatality rate of SARS-CoV-2 infection in a German

community with a super-spreading event. Medrxiv 2020.
(39)

Stringhini S, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva,

Switzerland (SEROCoV-POP): a population-based study. The Lancet 2020; 396(10247): 313319.
(40)

Folkh√§lsomyndigheten (Public Health Agency of Sweden). F√∂rsta resultaten om

antikroppar efter genomg√•ngen covid-19 hos blodgivare; June 18, 2020.
https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/juni/forstaresultaten-om-antikroppar-efter-genomgangen-covid-19-hos-blodgivare/.
(41)

Ward H, et al. Antibody prevalence for SARS-CoV-2 in England following first peak

of the pandemic: REACT2 study in 100,000 adults. Medrxiv 2020.
doi:10.1101/2020.08.12.20173690
(42)

Herzog S, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in

Belgium: a prospective cross-sectional study of residual samples. Medrxiv 2020.
doi:10.1101/2020.06.08.20125179.
(43)

Poll√°n M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,

population-based seroepidemiological study. The Lancet 2020; 396(10250): 535-544.
(44)

Pastor-Barriuso R, et al. SARS-CoV-2 infection fatality risk in a nationwide

seroepidemiological study. Medrxiv 2020. doi:10.1101/2020.08.06.20169722.
(45)

Italian National Institute of Statistics. Primi risultati dell‚Äôindagine di sieroprevalenza

SARS-CoV-2; August 3, 2020. http://www.salute.gov.it/imgs/C_17_notizie_4998_0_file.pdf.

32

medRxiv preprint doi: https://doi.org/10.1101/2020.10.25.20216671; this version posted October 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

(46)

Pagani G, et al. Seroprevalence of SARS-CoV-2 significantly varies with age:

Preliminary results from a mass population screening. Journal of Infection 2020: in press.
doi:10.1016/j.jinf.2020.09.021.
(47)

Instituto Superiore di Sanita (ISS). Epidemia COVID-19: Aggiornamento nazionale.

Roma; 30 giugno 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettinosorveglianza-integrata-COVID-19_30-giugno-2020.pdf.
(48)

Australian Government: Department of Health. Coronavirus (COVID-19) current

situation and case numbers. https://www.health.gov.au/news/health-alerts/novel-coronavirus2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers. Accessed 3
August, 2020.
(49)

Levin AT, et al. Assessing the Age Specificity of Infection Fatality Rates for COVID-

19: Meta-Analysis & Public Policy Implications. Cambridge MA: National Bureau of
Economic Research; July 2020, revised October 2020; Working Paper 27597.
http://www.nber.org/papers/w27597.
(50)

Valero M, Valero-Gil JN. Determinants of the Number of Deaths from COVID-19:

Differences between Low-Income and High-Income Countries in the Initial Stages of the
Pandemic. SSRN 2020. doi:10.2139/ssrn.3617049.
(51)

Grifoni A, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans

with COVID-19 disease and unexposed individuals. Cell 2020; 181(7): 1489-1501.

33

